Nivolumab is a typical ICPI that is an anti-programmed cell death protein 1 (PD-1) antibody designed to promote an immunologic reaction against cancer cells including melanoma, non-small cell lung cancer, and renal cell carcinoma (RCC) by blocking the activation of the PD-1-mediated pathway [1]. This evidence concerns the gene PDCD1 and renal cell carcinoma.